United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?

United Therapeutics Corporation (NASDAQ:UTHR) develops treatments for pulmonary arterial hypertension, a rare and dangerous high blood pressure in the lungs, with its Tyvaso franchise at the core. At about $23.5 billion in market value, it is one of the steadiest earners in biotech, and that is the whole point for index purposes. Most drug developers […]